Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients

Patients with Lupus share their health experiences within a secure registry to advance research, support better clinical decision-making, and improve patient outcomes

Alira Health and FORWARD


Framingham, Mass. – November 6, 2023 –
Alira Health, a global advisory and clinical research firm, and FORWARD, the National Databank for Rheumatic Diseases and largest patient-reported research databank for rheumatic disorders in the United States, announced today the launch of the enhanced Lupus Registry, enabling patients, caregivers, and research sponsors to gain better insights, and achieve better patient outcomes.

The collaboration with FORWARD and the Lupus Registry represents a significant stride along our transformative journey. We are privileged to work together in our shared mission to enhance the well-being of individuals living with Lupus.”
Jennifer Lannon Director, Patient Engagement and Advocacy, Alira Health

Lupus is a complex disease with diverse manifestation, limited treatment options and inequitable impact on the affected population. This makes research into patient experience, treatment patterns and long-term clinical outcomes particularly challenging. The registry will enable patients to securely and safely submit their health and symptom data, helping them to better manage their condition, and the de-identified data helps researchers design and drive new clinical studies to improve disease understanding, develop better treatments for Lupus and improve patient outcomes.

FORWARD has established a collaborative partnership with Alira Health for administration and expansion of the registry, along with data analysis and reporting. Alira Health will introduce innovative, streamlined data submission methods for patients via a mobile application known as Health Storylines™. The enhancement of this registry leverages technological advancements for an enhanced comprehension of Lupus. Patients will share their data through a structured registry questionnaire, and have the option to provide information about their day-to-day health experiences using the app and also to share their Electronic Health Records. This approach will enable researchers to gain more comprehensive insights into the real-life experiences of individuals living with Lupus.

Research sponsors will have the opportunity to accelerate and refine research by tapping into extensive longitudinal data and a robust recruitment channel for prospective studies (observational and interventional). This resource will enable them to explore new hypotheses and capture long-term outcomes. This approach empowers sponsors to assess the current disease burden and generate evidence on the impact of new and established treatments in a highly efficient way.

“Patient contributions to the registry will serve as a driving force for the exploration of novel approaches to Lupus treatment,” said Kaleb Michaud, PhD, Director, FORWARD. “With a commitment to global patient data privacy, individuals can now confidently and securely share their data, enabling research sponsors to make profound discoveries in the field of Lupus, potentially leading to enhanced outcomes and new treatment options.”

“We envision a future in which patients are empowered to personally manage their complete healthcare information, leading to more effective treatments, improved disease management, better overall health, and the ability to actively engage their support network,” commented Jennifer Lannon, Director, Patient Engagement and Advocacy, Alira Health. “The collaboration with FORWARD and the Lupus Registry represents a significant stride along this transformative journey. We are privileged to work together in our shared mission to enhance the well-being of individuals living with Lupus.”

FORWARD has engaged over 6,000 individuals with Lupus since their founding in 1998. Alira Health’s Health Storylines has engaged over 3,000 individuals with Lupus since launching in 2013. As part of the partnership, these individuals will all be invited to participate in the enhanced Lupus Registry on Health Storylines.

The patient registry will serve as a continuous, worldwide digital repository for symptoms and health-related information. This data is shared directly through online and mobile applications. The system guarantees data protection and de-identification, preventing the direct association of specific data points with individual members. The data is managed and maintained by Alira Health in partnership with FORWARD to ensure data accuracy, hygiene, and quality.

The results of data reporting will be shared with the members of the patient registry, allowing patients to gain insights into the collective outcomes experienced by the population with Lupus. Furthermore, all research findings that are published will be disseminated to the Lupus Community, giving them the opportunity to understand the role of the registry in fostering groundbreaking discoveries.

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, MedTech and Patient Advocacy clients with a full spectrum of services across their entire solutions lifecycle. Learn more at AliraHealth.com.

About FORWARD

FORWARD is an independent, non-profit research organization, and one of the largest and longest running patient-reported research databanks for rheumatic conditions. FORWARD works with patients, physicians, researchers, and industry to collect, analyze, and share real-world data designed to advance knowledge about the causes, treatment, costs, and outcomes of rheumatic conditions. Learn more at ForwardDatabank.org.

Related news

Multimedia November 28, 2023
How to Accelerate Lupus Solutions with RWD
Explore lupus solutions and real-world treatment impacts through a discussion on patient aspects and the role of technology in streamlining research efficiency.
Lupus Patient Centricity Real-World Evidence (RWE)
Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Events November 8, 2023
Spain Healthcare Innovation Summit
We will sponsor and speak at Spain Healthcare Innovation Summit, a premier event that brings together healthcare professionals from across Spain and beyond to discuss the latest developments(...)
Market Access Patient Centricity Spain
News November 6, 2023
Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients
Alira Health and FORWARD announced the launch of the enhanced Lupus Registry, enabling patients, caregivers, and research sponsors to gain better insights, and achieve better patient outcomes.
Patient Advocacy Patient Centricity Registry-based studies
News November 6, 2023
Alira Health Partners with the Patient Empowerment Network Enabling Cancer Patients to Take Control of their Health and Treatment
Alira Health and the Patient Empowerment Network announced their partnership in supporting those impacted by cancer with a mobile platform delivering essential support for their medical needs.
Oncology Patient Advocacy Patient Engagement
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Blog August 28, 2023
Mandatory Patient-Focused Listening Sessions with CMS: What Manufacturers Need to Know
To learn about patient-focused listening sessions, their potential impact, and how manufacturers can prepare, we spoke with our experts.
Drug Development Patient Advocacy Patient Engagement
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.